108 related articles for article (PubMed ID: 16942445)
1. Analysis of antitumor activity elicited by vaccination with combinations of interleukin-12 DNA with gp100 DNA or the chemokine CCL21 in vivo.
Elzaouk L; Pavlovic J; Moelling K
Hum Gene Ther; 2006 Aug; 17(8):859-70. PubMed ID: 16942445
[TBL] [Abstract][Full Text] [Related]
2. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model.
Nawrath M; Pavlovic J; Moelling K
J Mol Med (Berl); 2001 Apr; 79(2-3):133-42. PubMed ID: 11357937
[TBL] [Abstract][Full Text] [Related]
4. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
Yamanaka R; Xanthopoulos KG
DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
[TBL] [Abstract][Full Text] [Related]
5. Transgenic expression of human gp100 and RANTES at specific time points for suppression of melanoma.
Aravindaram K; Yu HH; Lan CW; Wang PH; Chen YH; Chen HM; Yagita H; Yang NS
Gene Ther; 2009 Nov; 16(11):1329-39. PubMed ID: 19626052
[TBL] [Abstract][Full Text] [Related]
6. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
Zhai Y; Yang JC; Spiess P; Nishimura MI; Overwijk WW; Roberts B; Restifo NP; Rosenberg SA
J Immunother; 1997 Jan; 20(1):15-25. PubMed ID: 9101410
[TBL] [Abstract][Full Text] [Related]
7. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity.
Neal ZC; Bates MK; Albertini MR; Herweijer H
Mol Ther; 2007 Feb; 15(2):422-30. PubMed ID: 17235322
[TBL] [Abstract][Full Text] [Related]
8. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
[TBL] [Abstract][Full Text] [Related]
9. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity.
Cochlovius B; Stassar MJ; Schreurs MW; Benner A; Adema GJ
Immunol Lett; 2002 Feb; 80(2):89-96. PubMed ID: 11750039
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
[TBL] [Abstract][Full Text] [Related]
11. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
[TBL] [Abstract][Full Text] [Related]
12. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.
Zhou WZ; Kaneda Y; Huang S; Morishita R; Hoon D
Gene Ther; 1999 Oct; 6(10):1768-73. PubMed ID: 10516727
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
14. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
[TBL] [Abstract][Full Text] [Related]
15. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
16. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
[TBL] [Abstract][Full Text] [Related]
17. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel17.
Nawrath M; Pavlovic J; Dummet R; Schultz J; Strack B; Heinrich J; Moelling K
Leukemia; 1999 Apr; 13 Suppl 1():S48-51. PubMed ID: 10232365
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
[TBL] [Abstract][Full Text] [Related]
19. Shikonin enhances efficacy of a gene-based cancer vaccine via induction of RANTES.
Chen HM; Wang PH; Aravindaram K; Chen YH; Yu HH; Yang WC; Yang NS
J Biomed Sci; 2012 Apr; 19(1):42. PubMed ID: 22494696
[TBL] [Abstract][Full Text] [Related]
20. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.
Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
